<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="974">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148468</url>
  </required_header>
  <id_info>
    <org_study_id>SCSPDgait</org_study_id>
    <nct_id>NCT05148468</nct_id>
  </id_info>
  <brief_title>Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease</brief_title>
  <official_title>Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease; a Randomized, Crossover, Double Blinded, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal cord stimulation (SCS) for Parkinson´s disease (PD) has been studied for a decade but&#xD;
      consensus on efficacy is still lacking, with the previous stimulation standard paresthesia&#xD;
      inducing threshold hampering adequate subject blinding. Considering that tonic stimulation&#xD;
      for pain has been shown to be efficacious for most patients on subthreshold stimulation&#xD;
      parameters we hypothesize a similar result with it´s use on PD. The investigators aim to:&#xD;
&#xD;
        1. Produce stronger evidence on SCS efficacy for PD in regards to gait, motor scores and&#xD;
           quality of life measures by incorporating subthreshold in a randomized cross over&#xD;
           placebo-controlled study with a large sample.&#xD;
&#xD;
        2. Identify predictors of good response to SCS therapy by performing trans spinal magnetic&#xD;
           stimulation (TSMS) before SCS implant and correlating the response to SCS to that of the&#xD;
           noninvasive TSMS.&#xD;
&#xD;
        3. Better provide biomarkers of SCS therapy through functional magnetic resonance imaging&#xD;
           and electroencephalographic mapping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gait impairment in Parkinson´s Disease (PD) is often refractory to standard medication&#xD;
      therapy and functional surgery options currently explored resulting in grave loss of&#xD;
      independence and quality of life. Spinal cord stimulation (SCS) has been explored for its&#xD;
      role in PD after enthusiastic animal studies and despite mixed initial results is currently a&#xD;
      very promising candidate for ameliorating hard to treat gait and balance disorders.&#xD;
&#xD;
      Consensus on tonic SCS efficacy is hampered mostly due to small samples and lack of&#xD;
      randomized controlled trials so far, and the impossibility of subject blinding due to&#xD;
      standard stimulation settings using currents over the paresthesia inducing threshold. Some&#xD;
      small studies already attempted subthreshold blinding and all resulted in non significant&#xD;
      results, however with no important difference when switching to suprathreshold settings, thus&#xD;
      raising the possibility of non responder subjects or inefficient therapy and calling for&#xD;
      additional exploration. The investigators aim to explore the feasibility of a placebo&#xD;
      controlled trial using subthreshold stimulation with a larger sample and produce stronger&#xD;
      evidence on SCS efficacy for PD.&#xD;
&#xD;
      Additionally, the possibility of non responder subjects will be explored by correlating the&#xD;
      degree of response to SCS to patient demographic characteristics including age, PD severity&#xD;
      and cognition, gait characteristics and the degree of response to trans spinal magnetic&#xD;
      stimulation (TSMS), a non invasive magnetic stimulation of upper thoracic spinal region,&#xD;
      aiming to identify prognostic factors for the therapy.&#xD;
&#xD;
      Finally, functional magnetic resonance imaging and electroencephalographic mapping will be&#xD;
      performed in order to identify biomarkers of SCS therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blinded randomized placebo controlled cross over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients and examiners will be blinded to stimulation status</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change on Timed Up and Go - Test 3 Meters (TUG-Test 3M)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the change in Timed Up and Go test times between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - Part II and III</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change in Unified Parkinson's Disease Rating Scale score part II and III between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting. MDS-PDRS part II is scored from 0 to 52 with higher scores associated with worse motor related daily activities performance. MDS-UPDRS part III is scored from 0 to 132 with higher scores associated with worse motor performance in parkinson related tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ39)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change in Parkinson's Disease Questionnaire 39 (PDQ-39) between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting. PDQ39 is score from 0 to 100%, higher values are associated with worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Freezing of Gait Questionnaire (NFOG-Q)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change in New Freezing of Gait Questionnaire (NFOG-Q) score between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting. NFOG-Q is scored from 0 to 28, higher values are associated with more freezing of gait.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 minute walk test</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change in gait speed change in 2 minute walk test between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting. Lower values correlate with better gait speed and mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Balance Evaluation Systems Test (Mini-BESTest)</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change in Mini Balance Evaluation Systems Test (Mini-BESTest) test scores between ON-stimulation and baseline and sham-stimulation and baseline in double blinded setting. Minimum value 0 and maximum value 108. Higher value is associated with better balance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Gait Disorders, Neurologic</condition>
  <arm_group>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation on active stimulation</intervention_name>
    <description>Active spinal cord stimulation on best individual parameters for patient</description>
    <arm_group_label>Active stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation on sham stimulation</intervention_name>
    <description>Spinal cord stimulation with parameters set to 0 mA</description>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed Parkinson´s Disease with Hoehn Yahr scale between 2,5 and 4,0&#xD;
&#xD;
          -  Main complaint of balance or freezing of gait&#xD;
&#xD;
          -  Score of 2 or more on subitem 3.11 of the MDS UPDRS scale concerning Freezing of Gait&#xD;
             severity.&#xD;
&#xD;
          -  Capable of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Frequent lower limb, lower back or hip pain scoring 3 or more on visual analog scale&#xD;
&#xD;
          -  Uncontrolled or serious comorbidities such as uncontrolled diabetes mellitus, renal&#xD;
             disease, anticoagulation, immunosuppression or other medical conditions that present a&#xD;
             contraindication for SCS surgery&#xD;
&#xD;
          -  Psychosis, uncontrolled depression (BDI &gt;14) or anxiety disorder (BAI &gt;14)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rubens G Cury, MD PHD</last_name>
    <phone>+55 11 26617877</phone>
    <email>rubens_cury@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafael B Carra, MD</last_name>
    <phone>+5511973106020</phone>
    <email>rafael.carra@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Agari T, Date I. Spinal cord stimulation for the treatment of abnormal posture and gait disorder in patients with Parkinson's disease. Neurol Med Chir (Tokyo). 2012;52(7):470-4.</citation>
    <PMID>22850494</PMID>
  </reference>
  <reference>
    <citation>Fuentes R, Petersson P, Nicolelis MA. Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. Eur J Neurosci. 2010 Oct;32(7):1100-8. doi: 10.1111/j.1460-9568.2010.07417.x. Review.</citation>
    <PMID>21039949</PMID>
  </reference>
  <reference>
    <citation>de Andrade EM, Ghilardi MG, Cury RG, Barbosa ER, Fuentes R, Teixeira MJ, Fonoff ET. Spinal cord stimulation for Parkinson's disease: a systematic review. Neurosurg Rev. 2016 Jan;39(1):27-35; discussion 35. doi: 10.1007/s10143-015-0651-1. Epub 2015 Jul 30. Review.</citation>
    <PMID>26219854</PMID>
  </reference>
  <reference>
    <citation>Fuentes R, Petersson P, Siesser WB, Caron MG, Nicolelis MA. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science. 2009 Mar 20;323(5921):1578-82. doi: 10.1126/science.1164901.</citation>
    <PMID>19299613</PMID>
  </reference>
  <reference>
    <citation>Thevathasan W, Mazzone P, Jha A, Djamshidian A, Dileone M, Di Lazzaro V, Brown P. Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson disease. Neurology. 2010 Apr 20;74(16):1325-7. doi: 10.1212/WNL.0b013e3181d9ed58.</citation>
    <PMID>20404313</PMID>
  </reference>
  <reference>
    <citation>Fénelon G, Goujon C, Gurruchaga JM, Cesaro P, Jarraya B, Palfi S, Lefaucheur JP. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord. 2012 Feb;18(2):213-4. doi: 10.1016/j.parkreldis.2011.07.015. Epub 2011 Aug 23.</citation>
    <PMID>21865071</PMID>
  </reference>
  <reference>
    <citation>Santana MB, Halje P, Simplício H, Richter U, Freire MAM, Petersson P, Fuentes R, Nicolelis MAL. Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. Neuron. 2014 Nov 19;84(4):716-722. doi: 10.1016/j.neuron.2014.08.061. Epub 2014 Oct 30.</citation>
    <PMID>25447740</PMID>
  </reference>
  <reference>
    <citation>Pinto de Souza C, Hamani C, Oliveira Souza C, Lopez Contreras WO, Dos Santos Ghilardi MG, Cury RG, Reis Barbosa E, Jacobsen Teixeira M, Talamoni Fonoff E. Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation. Mov Disord. 2017 Feb;32(2):278-282. doi: 10.1002/mds.26850. Epub 2016 Nov 10.</citation>
    <PMID>27862267</PMID>
  </reference>
  <reference>
    <citation>Akiyama H, Nukui S, Akamatu M, Hasegawa Y, Nishikido O, Inoue S. Effectiveness of spinal cord stimulation for painful camptocormia with Pisa syndrome in Parkinson's disease: a case report. BMC Neurol. 2017 Aug 3;17(1):148. doi: 10.1186/s12883-017-0926-y.</citation>
    <PMID>28774283</PMID>
  </reference>
  <reference>
    <citation>Samotus O, Parrent A, Jog M. Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson's Disease Patients. Mov Disord. 2018 May;33(5):783-792. doi: 10.1002/mds.27299. Epub 2018 Feb 14.</citation>
    <PMID>29442369</PMID>
  </reference>
  <reference>
    <citation>de Lima-Pardini AC, Coelho DB, Souza CP, Souza CO, Ghilardi MGDS, Garcia T, Voos M, Milosevic M, Hamani C, Teixeira LA, Fonoff ET. Effects of spinal cord stimulation on postural control in Parkinson's disease patients with freezing of gait. Elife. 2018 Aug 2;7. pii: e37727. doi: 10.7554/eLife.37727.</citation>
    <PMID>30070204</PMID>
  </reference>
  <reference>
    <citation>Kobayashi R, Kenji S, Taketomi A, Murakami H, Ono K, Otake H. New mode of burst spinal cord stimulation improved mental status as well as motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord. 2018 Dec;57:82-83. doi: 10.1016/j.parkreldis.2018.07.002. Epub 2018 Jul 6.</citation>
    <PMID>30017249</PMID>
  </reference>
  <reference>
    <citation>Mazzone P, Viselli F, Ferraina S, Giamundo M, Marano M, Paoloni M, Masedu F, Capozzo A, Scarnati E. High Cervical Spinal Cord Stimulation: A One Year Follow-Up Study on Motor and Non-Motor Functions in Parkinson's Disease. Brain Sci. 2019 Apr 3;9(4). pii: E78. doi: 10.3390/brainsci9040078.</citation>
    <PMID>30987170</PMID>
  </reference>
  <reference>
    <citation>Hubsch C, D'Hardemare V, Ben Maacha M, Ziegler M, Patte-Karsenti N, Thiebaut JB, Gout O, Brandel JP. Tonic spinal cord stimulation as therapeutic option in Parkinson disease with axial symptoms: Effects on walking and quality of life. Parkinsonism Relat Disord. 2019 Jun;63:235-237. doi: 10.1016/j.parkreldis.2019.02.044. Epub 2019 Mar 2.</citation>
    <PMID>30852148</PMID>
  </reference>
  <reference>
    <citation>Chakravarthy KV, Chaturvedi R, Agari T, Iwamuro H, Reddy R, Matsui A. Single arm prospective multicenter case series on the use of burst stimulation to improve pain and motor symptoms in Parkinson's disease. Bioelectron Med. 2020 Sep 28;6:18. doi: 10.1186/s42234-020-00055-3. eCollection 2020.</citation>
    <PMID>33005705</PMID>
  </reference>
  <reference>
    <citation>Lai Y, Pan Y, Wang L, Zhang C, Sun B, Li D. Spinal Cord Stimulation with Surgical Lead Improves Pain and Gait in Parkinson's Disease after a Dislocation of Percutaneous Lead: A Case Report. Stereotact Funct Neurosurg. 2020;98(2):104-109. doi: 10.1159/000505707. Epub 2020 Feb 25.</citation>
    <PMID>32097953</PMID>
  </reference>
  <reference>
    <citation>Prasad S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, Lozano AM, Fasano A. Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial. Mov Disord. 2020 Jun;35(6):1082-1083. doi: 10.1002/mds.28065. Epub 2020 Apr 20.</citation>
    <PMID>32311155</PMID>
  </reference>
  <reference>
    <citation>Cury RG, Carra RB, Capato TTC, Teixeira MJ, Barbosa ER. Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure? Mov Disord. 2020 Oct;35(10):1882-1883. doi: 10.1002/mds.28271.</citation>
    <PMID>33068473</PMID>
  </reference>
  <reference>
    <citation>Samotus O, Parrent A, Jog M. Long-term update of the effect of spinal cord stimulation in advanced Parkinson's disease patients. Brain Stimul. 2020 Sep - Oct;13(5):1196-1197. doi: 10.1016/j.brs.2020.06.004. Epub 2020 Jun 3.</citation>
    <PMID>32504828</PMID>
  </reference>
  <reference>
    <citation>Reis Menezes J, Bernhart Carra R, Aline Nunes G, da Silva Simões J, Jacobsen Teixeira M, Paiva Duarte K, Ciampi de Andrade D, Barbosa ER, Antônio Marcolin M, Cury RG. Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson's disease. J Clin Neurosci. 2020 Nov;81:306-309. doi: 10.1016/j.jocn.2020.10.001. Epub 2020 Oct 20.</citation>
    <PMID>33222935</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gait</keyword>
  <keyword>Parkinson´s disease</keyword>
  <keyword>Spinal Cord stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

